Systemische Therapie mit Kimmtrak beim metastasierten uvealen Melanom

Literatur
1 Chacón M, Pfluger Y, Angel M. et al. Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. Cancers (Basel) 2020; 12: 2362
2 Bechrakis NE, Bornfeld N, Heindl LM. et al. Uveal Melanoma – Standardised Procedure in Diagnosis, Therapy and Surveillance. Klin Monbl Augenheilkd 2021; 238: 761-772
3 Mor JM, Rokohl AC, Mauch C. et al. Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre. Klin Monbl Augenheilkd 2021; 238: 85-91
4 Khoja L, Atenafu EG, Suciu S. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370-1380
5 Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019; 29: 561-568
6 Martinez-Perez D, Viñal D, Solares I. et al. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. Cancers (Basel) 2021; 13: 5968
7 Damato BE, Dukes J, Goodall H. et al. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019; 11: 971
8 Carvajal RD, Nathan P, Sacco JJ. et al. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol 2022; 40: 1939-1948
9 Carvajal RD, Butler MO, Shoushtari AN. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 2022; 28: 2364-2373
10 Hassel JC, Piperno-Neumann S, Rutkowski P. et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2023; 389: 2256-2266
11 Nathan P, Hassel JC, Rutkowski P. et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021; 385: 1196-1206